A phase 2, multiarm study of anti-CD47 antibody, magrolimab, in combination with docetaxel in patients with locally advanced or metastatic solid tumors.

Authors

Vivek Subbiah

Vivek Subbiah

Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Vivek Subbiah , Ulka N. Vaishampayan , Sonam Puri , Lanjia Lin , Mark Chao , Giri Ramsingh , Shivaani Kummar , James F. Strauss , Sandip P. Patel

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session B: Urothelial Carcinoma

Track

Urothelial Carcinoma

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04827576

Citation

J Clin Oncol 40, 2022 (suppl 6; abstr TPS584)

DOI

10.1200/JCO.2022.40.6_suppl.TPS584

Abstract #

TPS584

Poster Bd #

N6

Abstract Disclosures